Costs and resource use of community-dwelling patients with Alzheimer’s disease in Japan: 18-month results from the GERAS-J study

Miharu Nakanishia Research Center for Social Science and Medicine Tokyo Metropolitan. Institute of Medical Science, Tokyo, Japan

https://orcid.org/0000-0001-6200-9279

Ataru Igarashib Department of Health Economics and Outcomes Research Graduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo, Japan;c Yokohama City University, Yokohama, Japan

Kaname Uedad Eli Lilly Japan K.K, Kobe, JapanCorrespondence[email protected]

https://orcid.org/0000-0003-1967-9829

Alan J. M. Brnabice Eli Lilly Australia Pty, Limited, West Ryde, Sydney, Australia

Taka Matsumurad Eli Lilly Japan K.K, Kobe, Japan

Kenichi Megurof Geriatric Behavioral Neurology Project, New Industry Creation Hatchery Center, and Division of Nuclear Medicine, Cyclotron Radioisotope Center, Tohoku University, Sendai, Japan;g Osaki-Tajiri SKIP Center, Osaki, Japan

Masahito Yamadah Department of Neurology and Neurobiology of Aging, Graduate School of Medical Sciences, Kanazawa University, Kanazawa, Japan

https://orcid.org/0000-0003-2416-5662

Masaru Mimurai Department of Neuropsychiatry, School of Medicine, Keio University, Tokyo, Japan

Heii Araij ALZCLINIC TOKYO, Tokyo, Japan

Tamas Treuerk Eli Lilly and Company, Budapest, Hungary

show all

Costs and resource use of community-dwelling patients with Alzheimer’s disease in Japan: 18-month results from the GERAS-J study

Supplemental Material

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Costs and resource use of community-dwelling patients with Alzheimer’s disease in Japan: 18-month results from the GERAS-J study

Supplemental Material

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date